ARIAD to Present at the Oppenheimer 20th Annual Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is scheduled to present at the Oppenheimer 20^th Annual Healthcare Conference being held at the Waldorf=Astoria Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, is scheduled to provide an overview of the Company and its progress in key programs in a corporate presentation on Tuesday, November 3 at 10:15 a.m. (ET).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for four weeks.

About ARIAD

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.